Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Apolipoprotein E Genotype and the Rate of Decline in Probable Alzheimer Disease

Apolipoprotein E Genotype and the Rate of Decline in Probable Alzheimer Disease Abstract The apolipoprotein E (ApoE) ε4 gene-dose effect1-3 involves the increased risk of late-onset Alzheimer disease (AD) in relation to the number of inherited copies of the ε4 allele; eg, persons who carry the ApoE ε3/3 genotype have lower risk than those with ε3/4 and those who carry ε3/4 have lower risk than those with ε4/4. This pattern of risk was identified for late-onset AD, defined as the onset of AD symptoms at or after age 60 years, and appears to apply to both familial and sporadic late-onset AD. The ε4 gene-dose effect does not directly translate into large differences in mean age at onset in groups of patients with AD, although it has sometimes been interpreted in this fashion.4 Specifically, Dal Forno et al4 use the similar mean ages at onset in a series of persons already affected with AD, those carrying 0,1, or 2 copies of References 1. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families . Science . 1993;261:921-923.Crossref 2. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease . Nature Genet . 1994;7:180-184.Crossref 3. Kuusisto J, Koivisto K, Kervinen K, et al. Association of apolipoprotein E phenotypes with late onset Alzheimer's disease: a population based study . BMJ . 1994;309:636-638.Crossref 4. Dal Forno G, Rasmusson X, Brandt J, et al. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease . Arch Neurol . 1996;53:345350. 5. Corder EH, Saunders AM, Strittmatter WJ, et al. Apolipoprotein E: survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease . Neurology . 1995;37:605-610. 6. Basun H, Grut M, Winblad B, Lannfelt L. Apolipoprotein ε4 allele and disease progression in patients with late-onset Alzheimer's disease . Neurosci Lett . 1995;183:32-34.Crossref 7. Norman J, Brookes AJ, Yates C, St Clair D. Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer's disease . Br J Psychiatry . 1995;167:533-536.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Neurology American Medical Association

Apolipoprotein E Genotype and the Rate of Decline in Probable Alzheimer Disease

Loading next page...
 
/lp/american-medical-association/apolipoprotein-e-genotype-and-the-rate-of-decline-in-probable-YyfY6D6Lq4
Publisher
American Medical Association
Copyright
Copyright © 1996 American Medical Association. All Rights Reserved.
ISSN
0003-9942
eISSN
1538-3687
DOI
10.1001/archneur.1996.00550110022004
Publisher site
See Article on Publisher Site

Abstract

Abstract The apolipoprotein E (ApoE) ε4 gene-dose effect1-3 involves the increased risk of late-onset Alzheimer disease (AD) in relation to the number of inherited copies of the ε4 allele; eg, persons who carry the ApoE ε3/3 genotype have lower risk than those with ε3/4 and those who carry ε3/4 have lower risk than those with ε4/4. This pattern of risk was identified for late-onset AD, defined as the onset of AD symptoms at or after age 60 years, and appears to apply to both familial and sporadic late-onset AD. The ε4 gene-dose effect does not directly translate into large differences in mean age at onset in groups of patients with AD, although it has sometimes been interpreted in this fashion.4 Specifically, Dal Forno et al4 use the similar mean ages at onset in a series of persons already affected with AD, those carrying 0,1, or 2 copies of References 1. Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families . Science . 1993;261:921-923.Crossref 2. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease . Nature Genet . 1994;7:180-184.Crossref 3. Kuusisto J, Koivisto K, Kervinen K, et al. Association of apolipoprotein E phenotypes with late onset Alzheimer's disease: a population based study . BMJ . 1994;309:636-638.Crossref 4. Dal Forno G, Rasmusson X, Brandt J, et al. Apolipoprotein E genotype and rate of decline in probable Alzheimer's disease . Arch Neurol . 1996;53:345350. 5. Corder EH, Saunders AM, Strittmatter WJ, et al. Apolipoprotein E: survival in Alzheimer's disease patients, and the competing risks of death and Alzheimer's disease . Neurology . 1995;37:605-610. 6. Basun H, Grut M, Winblad B, Lannfelt L. Apolipoprotein ε4 allele and disease progression in patients with late-onset Alzheimer's disease . Neurosci Lett . 1995;183:32-34.Crossref 7. Norman J, Brookes AJ, Yates C, St Clair D. Apolipoprotein E genotype and its effect on duration and severity of early and late onset Alzheimer's disease . Br J Psychiatry . 1995;167:533-536.Crossref

Journal

Archives of NeurologyAmerican Medical Association

Published: Nov 1, 1996

References